Target intelligence / Profile preview

Stratum corneum structural protein (None established; no common canonical abbreviation)

Target: None established; no common canonical abbreviation
Molecular classification: Other (structural protein), Cytoskeletal protein (keratin family), Aggregation protein (filaggrin), Cross-linking protein (involucrin, loricrin)

Overview

The stratum corneum is the skin’s outermost layer, composed mainly of corneocytes surrounded by lipids, with the cornified cell envelope formed from aggregated and cross-linked structural proteins such as keratin and filaggrin. These proteins provide strength, flexibility, and water impermeability, enabling the skin to act as a robust barrier against physical, chemical, and microbial threats. Filaggrin also generates natural moisturizing factors, while proteins like involucrin and loricrin reinforce the corneocyte envelope and regulate desquamation. Defects in these structural proteins (notably filaggrin mutations) are strongly linked to skin diseases, especially atopic dermatitis and other barrier-impairment disorders. No single molecule in this class serves as a canonical drug target, but these proteins jointly determine the stratum corneum’s resilience, hydration, and defense capacities.

Other names: Cornified envelope proteinsEpidermal structural proteinsSkin barrier proteinsStratum corneum proteins

Mechanism of action

Barrier repair (emollients restore lipid and protein matrix) Inflammatory suppression (corticosteroids reduce cytokine-mediated damage) No direct action against the structural proteins as a whole

Biological functions

Barrier functionMechanical protectionPrevention of water lossProtection against pathogens and toxinsUV protectionRegulation of desquamation (skin shedding)

Disease associations

Inflammation (e.g., atopic dermatitis due to filaggrin mutations)Infection (compromised barrier increases susceptibility)Other skin disorders (ichthyosis, psoriasis)

Safety considerations

Risk of increased skin permeability upon barrier dysfunction (allergen sensitization, infection)Irritation from harsh surfactants degrading structural proteinsBarrier repair strategies must avoid inducing further skin breakdown

Interacting drugs

Topical emollients and moisturizers (indirectly support structural proteins)

2 more in the full profile.

Biomarkers

Filaggrin mutation status (biomarker for atopic dermatitis)Transepidermal water loss (TEWL; indirect measure of barrier protein integrity)Corneocyte protein content (keratin, filaggrin) in skin biopsy

Beyond the preview

Go deeper on Stratum corneum structural protein (None established; no common canonical abbreviation).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stratum corneum structural protein (None established; no common canonical abbreviation).

Explore the full profile